HTR1A and metastatic prostate carcinoma: PAAD progression involves various serotonin receptor subtypes at distinct tumor phases, with significant HTR1A and HTR1B expression observed in aggressive PAAD characterized by high Gleason scores and metastatic prostate cancer [40].